证券代码：300181 证券简称：佐力药业 公告编号：2024-051 浙江佐力药业股份有限公司 第八届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江佐力药业股份有限公司（以下简称"公司"）第八届监事会第二次会议 于2024年7月26日在公司会议室以现场表决的方式召开。会议通知于2024年7月 16日以专人送达、电话、传真及电子邮件等相结合方式送达各监事。会议应参 加审议表决监事3人，实际参加审议表决监事3人，本次会议由监事会主席周城 华先生主持，会议的召开符合《公司法》、《公司章程》的有关规定。 二、监事会会议审议情况 1、审议通过《关于<公司 2024 年半年度报告及其摘要>的议案》 三、备查文件 表决结果：同意 3 票，反对 0 票，弃权 0 票，获得通过。 3、审议通过《关于回购公司股份方案的议案》 经审议，监事会认为：公司本次回购公司股份方案符合《公司法》《证券法》 《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第9号——回 购股份》等相关法律法规的规定，本次回购的股份拟用于后期实 ...

Financial Performance - The company's operating revenue for the first half of 2024 reached ¥1,428,254,689.36, representing a 41.21% increase compared to ¥1,011,458,568.59 in the same period last year[19]. - Net profit attributable to shareholders was ¥296,054,107.17, up 49.78% from ¥197,661,591.44 year-on-year[19]. - The net cash flow from operating activities increased by 74.81% to ¥215,347,293.72, compared to ¥123,191,852.79 in the previous year[19]. - Basic earnings per share rose to ¥0.4221, reflecting a 49.79% increase from ¥0.2818 in the same period last year[19]. - Total assets at the end of the reporting period were ¥3,894,078,073.37, a 7.36% increase from ¥3,627,038,970.51 at the end of the previous year[19]. - The weighted average return on equity improved to 10.48%, up from 7.14% in the previous year[19]. - The net profit after deducting non-recurring gains and losses was ¥292,102,892.52, a 50.78% increase from ¥193,733,354.17 year-on-year[19]. - The total profit reached 344.27 million yuan, up 50.53% compared to the same period last year[42]. - The company achieved operating revenue of 1,428.25 million yuan, a year-on-year increase of 41.21%[42]. Market Position and Product Development - The company's core product, Wuling Capsule, ranked first in market share at 14.69% in urban public hospitals for both 2022 and 2023, maintaining its leading position in the market[32]. - The company’s other product, Bailing Pian, improved its ranking in county-level public hospitals from 8th in 2022 to 6th in 2023, with a market share increase from 2.71% to 3.49%[32]. - The company has been recognized as a leading player in the pharmaceutical industry, with its products included in the first batch of "Zhejiang-produced Chinese medicine" industrial brands[32]. - The company is positioned to benefit from national policies aimed at promoting the development of traditional Chinese medicine, which are expected to create long-term growth opportunities in the industry[28]. - The company’s mission focuses on enhancing human health and contributing to the development of traditional Chinese medicine, emphasizing innovation and collaboration[31]. - The company’s market strategy includes leveraging its expertise in medicinal fungi to establish a strong presence in the pharmaceutical sector[31]. - The ongoing reforms in the healthcare system, including drug procurement and insurance policies, present both challenges and opportunities for the company in the evolving market landscape[31]. - The company ranked 48th in the "2023 Top 100 Chinese Traditional Medicine Enterprises" list published by the China Pharmaceutical Industry Association[33]. Research and Development - The company has initiated clinical trials for innovative TCM products, including Lingxiang tablets, which have received approval from the National Medical Products Administration[43]. - The company has applied for 4 new patents, including 2 invention patents, to strengthen its intellectual property portfolio[43]. - The company’s R&D center has been recognized as a provincial enterprise technology center and a provincial high-tech research and development center, indicating strong innovation capabilities[48]. - The company’s bio-fermentation technology for producing rare medicinal fungi has led to significant innovations and cost-effective production processes[48]. - The company plans to closely monitor industry policy changes and adjust its business strategies accordingly, focusing on enhancing coverage in hospital and OTC terminals[90]. - The company will continue to increase investment in R&D, optimize its innovation mechanisms, and strengthen partnerships with domestic research institutions to enhance its product pipeline[91]. Environmental and Social Responsibility - The company has established internal management systems for wastewater treatment and solid waste management to ensure compliance with environmental regulations[110]. - The company has developed an environmental self-monitoring plan and is connected to the ecological environment bureau's system for real-time monitoring[112]. - The company paid an environmental protection tax of 434.24 RMB for the year 2024[114]. - The company has committed to green development and has been actively involved in social responsibility initiatives[119]. - The company donated a total of 1 million RMB for social welfare activities during the reporting period[120]. - The company has been recognized with the "Charity Work Award" for 2023 by the Huzhou Moganshan High-tech Zone Management Committee[120]. Strategic Initiatives and Future Outlook - The company plans to expand its market presence by entering three new provinces by the end of 2024[95]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence[94]. - The company aims to enhance its digital marketing strategies, targeting a 40% increase in online sales channels by the end of 2024[94]. - The company has implemented new cost-control measures aimed at reducing operational expenses by 5% in the next fiscal year[197]. - Future guidance indicates a projected revenue growth of 5% for the next quarter, driven by new product launches[200]. - The company plans to invest RMB 59,000 million in the "Intelligent Traditional Chinese Medicine Production Base Construction and Upgrade Project" by June 30, 2025[79]. Corporate Governance and Management Changes - The company held its annual general meeting on May 10, 2024, with a participation rate of 23.12%[100]. - The company reported a change in management, with Wang Tao appointed as the new General Manager and Fu Guofu continuing as Executive Vice President[101]. - The company has emphasized compliance with legal regulations following a short-term trading violation involving a senior executive, with corrective measures implemented[129]. - The total number of shareholders at the end of the reporting period is 31,139[161]. - The largest shareholder, Yu Youqiang, holds 18.52% of the shares, totaling 129,890,463[161]. Financial Management and Fundraising - The total amount of raised funds is RMB 91,000 million, with a net amount of RMB 89,814.07 million after deducting related fees[75]. - The company has not changed the purpose of the raised funds, maintaining a 0.00% change ratio[74]. - The company has extended the completion period for some fundraising projects based on prudent principles, reflecting a careful approach to project management[46]. - The company has no overdue or unrecovered amounts from entrusted financial management, indicating effective cash management practices[84]. - The company has not reported any share repurchase progress during the reporting period[157].

2024 | 保荐人名称： | 国金证券股份有限公司 | 被保荐公司简称：佐力药业 | | --- | --- | --- | | 保荐代表人姓名：崔敏捷 | | 联系电话：021-68826021 | | 保荐代表人姓名：黄世瑾 | | 联系电话：021-68826021 | | 1.公司信息披露审阅情况 | | | --- | --- | | (1) 是否及时审阅公司信息披露文件 | 是 | | (2) 未及时审阅公司信息披露文件的次数 | 0 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | 是否督导公司建立健全规章制度（包括但不 (1) | | | 限于防止关联方占用公司资源的制度、募集资金 | 是 | | 管理制度、内控制度、内部审计制度、关联交易 | | | 制度） | | | (2) 公司是否有效执行相关规章制度 | 已有效执行相关制度 | | 3.募集资金监督情况 | | | (1) 查询公司募集资金专户次数 | 每月查询 | | (2)公司募集资金项目进展是否与信息披露文件 | 是 | | 一致 | | | 4.公司治理督导情况 | | | (1) 列席公司股东大会次数 | ...

证券代码：300181 证券简称：佐力药业 公告编号：2024-056 浙江佐力药业股份有限公司 关于回购公司股份方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 （3）拟回购股份的价格：不超过人民币 20 元/股（含）。 （4）拟回购股份的资金总额及资金来源：以自有资金不低于人民 20,000 万元（含）且不超过人民币 30,000 万元（含）进行回购。 重要内容提示： （1）拟回购股份的种类：公司已发行的人民币普通股（A 股）股票。 （2）拟回购股份的用途：股权激励计划。 浙江佐力药业股份有限公司（以下简称"公司"）拟使用自有资金以集中竞 价交易方式回购部分公司股份，具体内容如下： 1、回购方案的主要内容 （5）拟回购股份数量及占公司总股本的比例：以拟回购价格上限和回购金 额区间测算，回购股份数量为 1,000 万股至 1,500 万股，占公司总股本的比例为 1.43%至 2.14%。具体回购股份数量以回购期限届满或回购实施完成时实际回购 的股份数量为准。 （6）回购股份的实施期限：自董事会审议通过本次回购股份方案之日起 6 个月内。 3、相关风 ...

证券代码：300181 证券简称：佐力药业 公告编号：2024-049 股东 名称 是否为控 股股东或 第一大股 东及其一 致行动人 本次解除质 押股份数量 占其所持 股份比例 (%) 占公司 总股本 比例(%) 原质押 起始日 解除质押 日期 质权人 俞有强 是 43,000,000 33.10 6.13 2021 年 8 月 5 日 2024 年 7 月 23 日 浙股（杭州）企 业管理有限公司 合计 - 43,000,000 33.10 6.13 - - - 一、股东股份解除质押基本情况 | 俞有强 | 是 | 8,000,000 | 6.16 | 1.14 | 否 | 否 | 2024 7月24日 | 年 | 解除质 押之日 | 中信证券股 份有限公司 | 融资 担保 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 2024 | 年 | 解除质 | 中信证券股 | 融资 | | 俞有强 | 是 | 15,000,000 | 11.55 | 2.14 | 否 | 否 | ...

证券代码：300181 证券简称：佐力药业 公告编号：2024-048 浙江佐力药业股份有限公司 关于控股股东、实际控制人部分股份 解除质押及质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江佐力药业股份有限公司（以下简称"公司"或"本公司"）近日接到公 司控股股东、实际控制人俞有强先生的函告，获悉其所持有本公司的部分股份办 理了解除质押及质押业务，具体事项如下： 二、股东股份质押基本情况 | | 是否为 控股股 | | | | 是 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 占其 | 占公 | 否 | 是否 | | | | | | 股东 | 东或第 | 本次质押 | 所持 | 司总 | 为 | 为补 | 质押 | 质押 | | 质押 | | | 一大股 | | 股份 | 股本 | | | | | 质权人 | | | 名称 | | 数量 | | | 限 | 充质 | 起始日 | 到期日 | | 用途 | | | 东及 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [3]. Core Views - The company is positioned as a leader in the medicinal fungi pharmaceutical sector, focusing on the development and production of traditional Chinese medicine products, particularly those based on medicinal fungi [9][19]. - The growth model is driven by two core products: the "Wuling" series and the "Bailing" series, with a strong emphasis on innovation and market expansion [9][57]. - The company has demonstrated robust revenue and profit growth, with projected net profits of 5.05 billion, 6.32 billion, and 7.85 billion yuan for 2024, 2025, and 2026 respectively [9][50]. Financial Summary - Revenue growth from 1.805 billion yuan in 2022 to an estimated 2.453 billion yuan in 2024, reflecting a year-over-year growth rate of 26.3% [2]. - Net profit is projected to increase from 383 million yuan in 2023 to 505 million yuan in 2024, with a year-over-year growth rate of 31.8% [2]. - The gross margin is expected to stabilize around 68.6% to 69.2% from 2024 to 2026, while the net margin is projected to rise from 20.6% in 2024 to 22.5% in 2026 [2]. Business Strategy - The company has established a comprehensive production line for traditional Chinese medicine pieces, with over 1,000 product specifications [4]. - The company is actively involved in the research and formulation of national and provincial standards for traditional Chinese medicine, having completed 208 national and 127 provincial standard filings by the end of 2023 [4]. - The "Wuling" series has shown significant sales growth, with revenue increasing from 4.82 billion yuan in 2018 to 11.94 billion yuan in 2023, representing a compound annual growth rate (CAGR) of approximately 19.9% [46]. Market Position - The company holds a clear and experienced ownership structure, with the controlling shareholder holding 18.52% of the shares as of Q1 2024 [31]. - The medicinal manufacturing segment has consistently contributed over 85% of total revenue from 2018 to 2023, with a stable gross margin above 65% [37]. - The company’s products, particularly the "Wuling" series, have maintained a high gross margin of over 82% from 2018 to 2023, indicating strong profitability [54].

| --- | --- | --- | --- | --- | |-------------------|-------|-------|-------|-------| | | 2023A | 2024E | 2025E | 2026E | | | | | | | | | 7.6% | 20.3% | 22.0% | 20.6% | | | 33.1% | 36.8% | 26.0% | 25.9% | | 归属于母公司净利 | 40.3% | 31.9% | 26.0% | 25.9% | | | | | | | | 毛利率（ % ） | 68.4% | 70.9% | 71.2% | 71.4% | | % ） | 19.7% | 21.6% | 22.3% | 23.3% | | （ % ） | 14.0% | 15.6% | 16.4% | 17.2% | | （ % ） | 10.2% | 13.5% | 13.9% | 14.3% | | | | | | | | 资产负债率（ % ） | 23.5% | 16.0% | 15.7% | 15.3% | | 净负债比率（ % ） | 30.8% | ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the benchmark index within the next six months [20][31]. Core Insights - The company is projected to achieve significant revenue growth, with an estimated revenue of approximately 14.26 billion yuan for the first half of 2024, representing a year-on-year increase of 41% [7]. - The net profit attributable to the parent company for the same period is expected to be between 2.95 billion and 3.10 billion yuan, reflecting a growth of 49.24% to 56.83% year-on-year [7]. - The company is experiencing robust growth in its product lines, particularly in the sales of Wu Ling capsules and Ling Ze tablets, with a notable increase in sales from traditional Chinese medicine slices [7][21]. Financial Projections - Revenue projections for 2023 to 2026 are as follows: 1,942 million yuan in 2023, 2,503 million yuan in 2024, 3,069 million yuan in 2025, and 3,725 million yuan in 2026, with growth rates of 7.61%, 28.86%, 22.60%, and 21.39% respectively [10][31]. - The net profit attributable to the parent company is forecasted to be 382.94 million yuan in 2023, increasing to 530.16 million yuan in 2024, 691.48 million yuan in 2025, and 886.49 million yuan in 2026, with growth rates of 40.27%, 38.45%, 30.43%, and 28.20% respectively [10][31]. - The earnings per share (EPS) are expected to rise from 0.55 yuan in 2023 to 1.26 yuan in 2026 [10][31]. Market Performance - The stock has shown a performance decline of 27% over the past year, with a current price of 15.55 yuan [5][17]. - The company has a total market capitalization of 10.9 billion yuan and a circulating market value of 9.3 billion yuan [18]. Company Overview - The company operates in the pharmaceutical and biotechnology sector, focusing on the development and sales of traditional Chinese medicine products [29].

Financial Forecast - The company forecasts a net profit attributable to shareholders between RMB 295 million and RMB 310 million for the first half of 2024, representing a year-on-year growth of 49.24% to 56.83% compared to RMB 197.66 million in the same period last year[6] - The net profit after deducting non-recurring gains and losses is expected to be between RMB 291 million and RMB 306 million, indicating a year-on-year increase of 50.23% to 57.97% from RMB 193.73 million last year[6] - The impact of non-recurring gains and losses on the company's net profit is estimated to be around RMB 3.95 million[16] Revenue Growth - The company achieved approximately 41% year-on-year growth in operating revenue during the reporting period, driven by strong sales of core products including Wuling Capsules and Lingze Tablets[16] - Sales revenue from traditional Chinese medicine (TCM) decoction pieces significantly increased due to a surge in online hospital sales in June, contributing to the overall revenue growth[16]